Sangamo Therapeutics (NASDAQ:SGMO) Given New $5.00 Price Target at Truist Financial

Sangamo Therapeutics (NASDAQ:SGMO) had its target price decreased by Truist Financial from $7.00 to $5.00 in a research note published on Thursday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the company. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, January 2nd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Stock Down 2.5 %

Shares of NASDAQ:SGMO opened at $1.16 on Thursday. The firm has a 50-day simple moving average of $1.81 and a 200 day simple moving average of $1.32. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The company has a market cap of $242.03 million, a PE ratio of -1.55 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same period last year, the business posted ($0.34) earnings per share. As a group, research analysts forecast that Sangamo Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Shelton Wealth Management LLC acquired a new position in Sangamo Therapeutics during the 4th quarter worth $29,000. Meritage Portfolio Management increased its position in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the period. XTX Topco Ltd raised its holdings in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Sangamo Therapeutics in the 3rd quarter valued at about $150,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.